Association between expression of the Bone morphogenetic proteins 2 and 7 in the repair of circumscribed cartilage lesions with clinical outcome by Schmal, Hagen et al.
RESEARCH ARTICLE Open Access
Association between expression of the Bone
morphogenetic proteins 2 and 7 in the repair of
circumscribed cartilage lesions with clinical
outcome
Hagen Schmal
*, Philipp Niemeyer, Jörn Zwingmann, Fabian Stoffel, Norbert P Südkamp, Alexander T Mehlhorn
Abstract
Background: Although there is much known about the role of BMPs in cartilage metabolism reliable data about
the in vivo regulation in natural and surgically induced cartilage repair are still missing.
Methods: Lavage fluids of knee joints of 47 patients were collected during surgical therapy. 5 patients had no
cartilage lesion and served as a control group, the other 42 patients with circumscribed cartilage defects were
treated by microfracturing (19) or by an Autologous Chondrocyte Implantation (23). The concentrations of BMP-2
and BMP-7 were determined by ELISA. The clinical status was evaluated using the IKDC Score prior to and 1 year
following the operation.
Results: High level expression in the control group was found for BMP-2, concentrations of BMP-7 remained below
detection levels. No statistical differences could be detected in concentrations of BMP-2 or BMP-7 in the lavage
fluids of knees with cartilage lesions compared to the control group. Levels of BMP-7 did not change after surgical
cartilage repair, whereas concentrations of BMP-2 statistically significant increased after the intervention (p < 0.001).
The clinical outcome following cartilage regenerating surgery increased after 1 year by 29% (p < 0.001). The
difference of the IKDC score after 1 year and prior to the operation was used to quantify the degree of
improvement following surgery. This difference statistically significant correlated with initial BMP-2 (R = 0.554,
p < 0.001) but not BMP-7 (R = 0.031, n.s.) levels in the knee joints.
Conclusions: BMP-2 seems to play an important role in surgically induced cartilage repair; synovial expression
correlates with the clinical outcome.
Background
Circumscribed cartilage defects are considered as an
initial event in the progress of osteoarthritis (OA) [1]. In
the last decades different methods have been developed
for treatment of this pathology. The Autologous Chon-
drocyte Implantation (ACI) and microfracturing are
regarded as established procedures with documented
success in prevention of OA-development. Despite clini-
cal improvement one-third of the patients show early
radiographic signs of OA five years after surgery inde-
pendent from used kind of surgical management [2];
this indicates a certain potential for further necessary
treatment perfection. Even though there is much known
about cartilage metabolism including significant regulat-
ing mediators reliable data about in vivo regulation of
natural cartilage repair and consequences of surgical
interventions are still missing. Measurement of synovial
mediator levels in the course of cartilage surgery seems
to be a sufficient way to verify the so far collected data
of in vitro or animal experiments. Therefore, this clinical
study was initiated, in which lavage fluids of knee joints
with cartilage lesions were prospectively collected and
cytokine content was analyzed. After publication of the
results gained for the regulators of cartilage metabolism
bFGF and IGF-I [3], this article focuses on the role of
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BMP-7) that both are recognized as candidate growth
factors with good potential in cartilage tissue engineer-
ing as well as cartilage repair.
BMP-2 and BMP-7 belong to the transforming
growth factor-beta (TGF-b) superfamily, consisting of
TGF-bs, growth differentiation factors, BMPs, activins,
inhibins, and glial cell line-derived neurotrophic factor
[4]. BMPs have been identified as very potent inducers
of bone, but since then it has become evident that
their function is not limited to skeletal development
[5]. BMP-2 expression is not only found in mesenchy-
mal condensation in embryonic development [6], but is
also able to induce chondrogenesis in human mesench-
ymal stem cells in culture [7]. For cartilage reparative
reasons, BMP-2 can be used to induce chondrogenesis
by coating scaffolds with BMP-2 before implantation
[8]. Thereby, the scaffold itself can be replaced by the
original tissue. This can be combined with culturing
mesenchymal stem cells or tissue specific cells on the
coated scaffold to gain de novo t i s s u ef o r m a t i o ni nt h e
scaffold [9]. Mechanical injury was found to upregulate
BMP-2 as well as BMP-2 signaling in human cartilage
explants [10]. This could indicate that BMP-2 is upre-
gulated as a reparative response but could also indicate
that BMP-2 is merely upregulated as a pathological
side effect, thereby further stimulating injury. BMP-7,
also known as osteogenic protein-1 (OP-1) has demon-
strated a great potential in bone repair applications.
Both BMPs received the regulatory approval as com-
mercially available proteins supporting bone repair i.e.
in case of delayed union. It has been shown that BMP-
7 also exhibits characteristics as a cartilage anabolic
factor because of the ability to induce matrix synthesis
and promote repair in cartilage. Data collected so far
suggest a significant role for BMP-7 in cartilage repair
concerning both articular and disc cartilage applica-
tions [11].
The purpose of this study was the in vivo evaluation
of the potentially chondro-protective and chondro-ana-
bolic cytokines BMP-2 and BMP-7 in knees with cir-
cumscribed cartilage lesions and to determine if the
cytokine profiles correlate with the clinically assessed
knee function. Since the expression patterns for aggre-
can, bFGF, IGF-I, and IL-1b and the regulation of the
intraarticular total protein content have already been
characterized and published [3], correlations of these
proteins with the clinical outcome were evaluated in
addition to the analysis of BMP-2 and 7. Furthermore,
the question should be answered whether surgical pro-
cedures of cartilage regeneration lead to an up-regula-
tion of both BMPs that in future might be used as a
prognostic factor or to support cartilage healing.
Methods
Study design
The study was performed as previously described [3].
Briefly, 47 patients were enrolled in a prospective clini-
cal trial between August 2006 and September 2007.
Selection of patients followed the criteria as defined
beneath.
Inclusion criteria: performance of an arthroscopy of
the knee joint, patients in the control group had no car-
tilage lesion in MRI and diagnostic arthroscopy, patients
undergoing microfracturing or ACI had full thickness
cartilage lesions graded III and IV according to ICRS
classification [12] of various size, agreement to partici-
pate in the study, age > 17 years and < 66 years (as
recommended [13])
Exclusion criteria: alcohol or drug abuse, mental retar-
dation with incapability to complete the necessary self-
reports, joint effusion > 30 ml, persistent knee instabil-
ity, infection
The study was approved by the Ethical board of the
University of Freiburg (AN-EK-FRBRG-335, study num-
ber DRKS00000365 and UKF001822). An informed con-
sent was obtained from every subject included in the
study.
Operation protocols
The ACI surgical technique has been well defined in
numerous publications [13-15]. In all patients a matrix
(Chondro-Gide®, Geistlich Biomaterials, Wolhusen, Swit-
zerland) associated technique for chondrocyte fixation
has been used. Microfractures were generated with spe-
cially bent awls (Chondropic™, Arthrex®, Karlsfeld, Ger-
many) by creating V-shaped perforation holes with a
diameter of 1.5-2 mm at a distance of 3 mm (3-4 holes/
cm
2) [16]. The applied kind of cartilage surgery was
chosen depending on defect size and depth according to
the schema of therapy as previously published [3].
Specimen collection
Synovial lavage fluids of knee joints of patients under-
going surgery were intraoperatively collected. Before
starting the procedure, 20 ml of sterile physiologic saline
was instilled into the joint cavity. The saline was mixed
within the joint by repeated passive flexion-extension
and repeated manipulation of the supra-and infrapatellar
regions, and then was aspirated as described by Geborek
et al.[17]. This method has been successfully used by a
variety of other groups [18-20]. The total volume aspi-
rated was recorded (6.0-10.5 ml). Specimen were centri-
fuged in order to separate the cells and then stored
frozen at -80°C until analyzed. An intraarticular drainage
was usually placed; the collected fluid in the drainage
bottles was used for analysis of mediator concentrations
Schmal et al. BMC Musculoskeletal Disorders 2010, 11:170
http://www.biomedcentral.com/1471-2474/11/170
Page 2 of 8at day 1 and 2 post surgery. Drainages were removed
according to medical necessity defined by the secretion
volume per day (< 50 ml/24 h).
Characterization of patients
5 patients undergoing a diagnostic arthroscopy for
unspecific knee complains had no cartilage lesion and
served as a control group, in case of the other
42 patients the cartilage defects were treated by micro-
fracturing (19 patients) or by an Autologous Chondro-
cyte Implantation (23 patients). No patient was operated
for a fracture. The average age of the patients with carti-
lage lesions was 42 ± 10 years, the gender distribution
was equal (21/21). The average age of the control group
was 30 ± 12 years; the male individuals slightly prevailed
(2/3). The body mass index (BMI) of the intervention
group was 26.9 ± 3.5, the BMI of the control group was
25.0 ± 3.74. Outcome measures were the Lysholm Score
[21], the IKDC Score [22], the Noyes Score [23], the
Medical Outcomes Study Short Form-36 (SF-36), and
visual analog scales (VAS) for knee pain strength and
frequency. Of the 42 patients with surgically treated car-
tilage defects initially entered into the study protocol, 1-
year follow-up data were available in 38 patients (84%).
Four patients, two in each intervention group, refused
the postoperative follow-up. The questionnaire was
done not earlier than after 12 months and not later than
13 months after surgery.
Grading of cartilage lesion
The amount of chondral damage was graded from 0 to
4 based on the ICRS classification [12] Grade 0 repre-
sents normal articular cartilage and grade I shows
superficial lesions as soft indentation and/or superficial
fissures and cracks. A grade II defect is a partial-thick-
ness defect; it features lesions extending down to less
than 50% of cartilage depth. With grade III defects,
there are cartilage defects extending down to more than
50% of cartilage depth as well as down to the calcified
layer, and down to but not through the subchondral
bone. Blisters are included in this grade. In grade IV
injuries, the subchondral bone is exposed and ruptured.
The total area of chondral defect per patient was calcu-
lated by adding the regions with grad III and grade IV
lesions. According to this standardized choice of treat-
ment the average defect sizes were 3.4 ± 2.0 cm
2 in case
of microfracturing, and 6.1 ± 2.6 cm
2 in case of ACI
(p < 0.001).
ELISAs for BMP-2, BMP-7, bFGF, IGF-1, IL-1b, Aggrecan,
BCA (bicinchoninic acid) Protein Assay
In order to measure concentrations of the indicated pro-
teins, commercially available ELISA kits provided by
R&D Systems (Wiesbaden-Nordenstadt, Germany) for
BMP-2, BMP-7, bFGF, IGF-I, IL-1b and BioSource (Bio-
Source Deutschland GmbH, Solingen, Germany) for
aggrecan were used according to the manufacturers’
instructions. Briefly, the assay employs the quantitative
sandwich enzyme immunoassay technique. A specific
MAb was pre-coated onto a microplate. Supernatants
were applied to the wells and, after washing, an HRP-
conjugated specific Ab was added to the wells. Following
the next wash, color development was proportional to
protein concentration and was calculated by comparison
with a standard. A colorimetric method was used in
order to quantify total protein amount in the lavage
fluids. The bicinchoninic acid (BCA) assay was available
in kit form from Pierce (Rockford, Ill., USA) and was
used according to the manufacturers’ instructions. In
principle, BCA serves the purpose of the Folin reagent
in the Lowry assay, namely to react with complexes
between copper ions and peptide bonds to produce a
purple end product. Extinction was read at 562 nm
within one hour.
Statistics
All values were expressed as mean ± standard deviation.
Data sets were examined with one-and two-way analysis
of variance (ANOVA) and individual group means of
protein or cytokine concentrations were then compared
with the unpaired or paired Student’s t-test, individual
group means of scores were compared with the Wil-
coxon rank sum test. Normal probability plots were
done on all data sets and correlation determined by
either calculating the Pearson (R)-or the Spearmen
(Rho) coefficient depending on distribution. The power
for comparing two means based on the normal approxi-
mation method was reported where indicated. Statistical
significance was defined when P < 0.05.
Results
Study parameters
The clinical outcome following regenerative cartilage
surgery after 1 year was evaluated using the IKDC and
the Lysholm Score. The IKDC Score increased by 29%
for all patients undergoing either an ACI or microfrac-
turing from 34.6 ± 15.1 points to 49.1 ± 17.5 points (n
= 38, p = 0.0002). The increase for patients treated by
ACI was 29% (n = 21, p = 0.0029), for patients under-
going microfracturing 30% (n = 17, p = 0.026). The
Lysholm Score increased by 21% for all patients under-
going either an ACI or microfracturing from 52.9 ± 21.1
points to 67.4 ± 19.1 points (n = 38, p = 0.004). The
increase for all ACI patients was 18% (n = 21, p = 0.03),
for all patients treated by microfracturing 26% (n = 17,
p = 0.03). Furthermore, sports activities were evaluated
using the Noyes Score; a trend for an increase without
statistical significance (preoperative 215 ± 74.81 points
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was seen when assessing all patients together indepen-
dent on kind of surgery. The effect of operative treat-
ment on pain perception wase x a m i n e du s i n gav i s u a l
analogue scale. Both pain-strength and pain-frequency
improved statistically significant by 30% (6.5 ± 2.0 vs.
4.5 ± 2.4, n = 38, p = 0.00025) and 25% (7.6 ± 2.1 vs.
5.7 ± 2.2, n = 38, p = 0.00029), respectively. In order to
evaluate the influence of the knee function improvement
on life quality the SF36 was used. An increase for the
physical health (34 ± 9 vs. 38 ± 10, n = 38, p = 0.08,
9.3%) and the mental health (50 ± 11 vs. 51 ± 11, n =
38, p = 0.68, 1.4%) was found without statistical signifi-
cance. The data are summarized in table 1.
BMP-2
The average concentration of BMP-2 in the lavage fluids
of knee joints with cartilage lesions was 120.60 ± 65.22
pg/ml (n = 42), this was not statically significant differ-
ent from the concentrations in the knees with intact
cartilage (110.07 ± 26.16 pg/ml, n = 5, p = 0.72, power
9.43%). BMP-2 expression did not correlate with carti-
lage defect size; average expression in both intervention
groups (ACI and microfracturing) did not statistically
significant differ (121.90 ± 83.44 pg/ml vs. 119.03 ±
34.30 pg/ml, p = 0.14). At day 1 following surgery an
average BMP-2 concentration of 185.07 ± 89.98 pg/ml
(n = 28) was measured what means a statistically signifi-
cant increase (p < 0.0001, power 91.3%) of BMP-2 levels
after surgery. BMP-2 concentrations in the knee joints
remained at a high level compared to baseline at day 2
following surgery (296.14 ± 64.19 pg/ml, n = 6,
p < 0.0001, power 100%, figure 1).
BMP-7
In all knees of the control group concentrations of
BMP-7 did not reach detection levels. In the knees with
chondral defects the average BMP-7 concentrations
were very low (8.56 ± 24.22 pg/ml), in 26 knees with
cartilage defects BMP-7 concentrations were below the
detection level (figure 2). BMP-7 expression did not
correlate with cartilage defect size; average expression in
both intervention groups did not statistically significant
d i f f e r( 0 . 0 1±0 . 2 2p g / m lv s .8 . 5 6±2 4 . 2 2p g / m l ,p=
0.44, power 57.94%). There was no statistically signifi-
cant change in BMP-7 levels at day 1 post surgery (8.56
± 24.22 pg/ml vs. 57.25 ± 137.89 pg/ml, n = 28, p =
0.09, power 46.56%), and no significant difference of
BMP-7 levels comparing day 1 and day 2 (6.53 ± 7.23
pg/ml, n = 6, p = 0.26, power 5.98%) after the operation.
Correlation of cytokine levels with clinical parameters
For the analysis of a possible association between
initial synovial cytokine levels and the clinical outcome
after 1 year the statistical correlation was calculated.
The clinical outcome was defined as the difference of
the IKDC or the Lysholm Score after 1 year and prior
to the operation that mirrors the individual improve-
ment for each case. There was a statistically significant
medium correlation between initial BMP-2 levels and
the IKDC Score differences with a Pearson coefficient
of 0.554 (p = 0.0003, figure 3), and a significant low
correlation of BMP-2 concentrations with the Lysholm
Score differences with a Pearson coefficient of 0.378 (p
= 0.019). The analysis of the treatment subgroups
showed a high correlation of BMP-2 levels with the
IKDC Score differences in the patients treated by
microfracturing (R = 0.822, p = 0.00005) and a med-
ium correlation for the patients treated by ACI (R =
0.535, p = 0.01). Furthermore, the correlation analysis
has been performed for the total protein content and
the concentrations of aggrecan, bFGF, IGF-I, and IL-1b
(n = 38). None of these intraarticular measured pro-
teins demonstrated a statistically significant association
with the clinical outcome defined by the differences of
the IKDC Scores or the Lysholm Score (table 2).
Quantification of these cytokines and data about post-
operative regulations have already been published [3].
Neither synovial BMP-2 nor BMP-7 levels correlated
with age (n = 47, R = 0.26, p = 0.29 and R = 0.06, p =
0.60) or BMI (n = 47, R = 0.10, p = 0.50 and R = 0.22,
p = 0.13).
Table 1 Overview about clinical outcome parameters
Score Preoperatively Postoperatively P Difference
IKDC 34.6 ± 15.1 49.1 ± 17.5 <0.001 29%
Lysholm 52.9 ± 21.1 67.4 ± 19.1 <0.01 21%
Noyes 215 ± 75 235 ± 59 0.06, n.s. 8.5%
Pain Strength (VAS) 6.5 ± 2.0 4.5 ± 2.4 <0.001 30%
Pain Frequency (VAS) 7.6 ± 2.1 5.7 ± 2.2 <0.001 25%
SF36 pcs (physical health) 34 ± 9 38 ± 10 0.08, n.s. 9.3%
SF36 mcs (mental health) 50 ± 11 51 ± 11 0.68, n.s. 1.4%
Overview about clinical outcome parameters comparing preoperative situation with the status after 1 year (VAS evaluation based on a visual analog scale,
physical component summary -pcs and mental component summary mcs)
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In order to look for possible regulative associations
between the investigated cytokines the statistical correla-
tion between intraarticular levels of IL-1b, IGF-I, bFGF
and BMP-2 and -7 was calculated. There was no
statistically significant correlation between synovial con-
centrations of IL-1b,I G F - I ,b F G Fa n dt h ee x a m i n e d
BMPs (n = 47, p > 0.08 for all correlations).
Discussion
Many in vitro studies and animal experiments gave sig-
nificant insights into the role of BMP-2 and BMP-7 in
cartilage metabolism and repair; however, data about
in vivo regulation in humans are ambiguous or still miss-
ing for certain clinical situations. Therefore, data about
intraarticular levels of BMP-2 and BMP-7 in knees with
circumscribed cartilage lesions and their correlation with
clinical scores are introduced. Although for both exam-
ined BMPs anabolic effects on cartilage were described
the data presented suggest a more heterogeneous picture.
Our data demonstrate significant levels of BMP-2 in
the synovial fluid of all knees without dependency of the
presence or the size of a cartilage lesion. This generally
indicates a role for BMP-2 in joint metabolism. Further-
more, increased concentrations of BMP-2 were
Figure 1 BMP-2 Course. BMP-2 content in lavage fluids of knee
joints without cartilage lesions (control, n = 5), with cartilage
damage (n = 42), following cartilage surgery at day 1 (n = 28) post
operation (po), and following cartilage surgery at day 2 (n = 6) post
operation. Groups were compared as indicated by the connecting
lines, significance levels are specified.
Figure 2 BMP-7 Course. BMP-7 content in lavage fluids of knee
joints without cartilage lesions (control, n = 5), with cartilage
damage (n = 42), following cartilage surgery at day 1 (n = 28) post
operation (po), and following cartilage surgery at day 2 (n = 6) post
operation. Groups were compared as indicated by the connecting
lines, significance levels are specified.
Figure 3 Association BMP-2 and IKDC Score. Significant positive
correlation between differences of the IKDC Score evaluated initially
and after 1 year and initial intraarticular BMP-2 concentrations in all
patients undergoing ACI or microfracturing (R = 0.554, p < 0.001)
Table 2 Overview about the correlation strength between
the changes of the IKDC Score and the initial
intraarticular cytokine levels
Cytokine R/Rho P
Protein -0.1174 n.s.
Aggrecan -0.1256 n.s.
BMP-2 0.5537 <0.001
BMP-7 0.0307 n.s.
IL-1b 0.0567 n.s.
bFGF -0.2218 n.s.
IGF-I -0.1013 n.s.
Overview about the correlation strength between the changes of the IKDC
Score evaluated initially and after 1 year with initial intraarticular cytokine
levels of BMP-2, BMP-7, IL-1b, bFGF, IGF-I, aggrecan and the total protein
content. The only statistically significant correlation was found in case of BMP-
2 (R-Pearson coefficient, Rho Spearmen coefficient).
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This might be explained as a consequence of the surgi-
cal manipulation of the cartilage defect boarder and the
arthrotomy as it has been shown for bFGF, IGF-I or IL-
1b [3]. But BMP-2 was the only intraarticular cytokine
which correlated with the degree of clinical improve-
ment measured by the IKDC Score. Since it has been
shown that the clinical outcome correlates with the
degree of cartilage regeneration [24] it may be con-
cluded that BMP-2 plays a significant role in cartilage
repair and metabolism. This is in concordance with
other studies showing BMP-2 stimulated murine proteo-
glycan synthesis and BMP-2 induced enhancement of
collagen type II expression in chondrocytes seeded in
alginate [25,26]. Also, in species like rats and humans,
BMP-2 was able to stimulate the chondrogenic pheno-
type on the mRNA level and induced cartilage extracel-
lular matrix proteoglycan production [27,28]. Further
studies [29] have added a partial catabolic effect on car-
tilage ECM indicating a regulative role for BMP-2 in
ECM maintenance, especially during inflammatory
induced turnover. This was confirmed by a study that
demonstrated a decisive role for BMPs in osteophyte
formation and synovial thickening during OA [30],
although the presented data do not allow concluding
that BMP-2 plays an important role in the onset of OA,
because healthy patients also expressed intraarticular
BMP-2. Similar to the effects of BMP-2 stimulation of
cartilage-specific extracellular proteins as collagens type
II and VI, aggrecan, decorin, fibronectin, hyaluronan
[31-34] has been shown in vitro for BMP-7 (OP-1). It
induced anabolic responses in normal and OA chondro-
cytes from both young and old donors and did not
cause expression of cartilage hypertrophy markers or
changes in their chondrogenic phenotype [35-37]. BMP-
7 was synthesised by human articular chondrocytes
[36,38] of different age and various degrees of degenera-
tion including OA, but the level of gene and protein
expression was dramatically reduced with cartilage aging
and degenerative destruction [36,37]. BMP-7 was mainly
localized in the cartilage layer [38], but was also
detected in the synovial knee fluid of patients with OA
and rheumatoid arthritis (RA) [18]. This articular distri-
bution suggests a decisive paracrine effect of BMP-7,
correlating with the finding that intraarticular measured
levels are lower than the effective concentrations deter-
mined in vitro [39]. In conformity with our data the
mature and active BMP-7 could not be found in human
synovial fluid of normal knees in a recently published
study [18]. The degree of degenerative changes seems to
influence the intraarticular concentration and possibly
induces the conversion of a BMP-7 pro-form into the
mature and active protein [18]. This is supported by the
data of Honsawek et al., who described increased
BMP-7 levels in knees of patients with progressive OA
[19] The circumstance that in our trial only patients
with circumscribed cartilage lesions were included (and
patients with advanced OA were excluded) may make
clear why synovial concentrations were mainly found
below the detection level and, therefore, did not corre-
late with the clinical score. Since for both examined
BMPs pro-forms [40] have been described, the role and
function of these precursor proteins still need to be
analysed.
The statistically significant correlation of BMP-2 levels
with the clinical outcome was only found using knee
specific scores. In contrast, scores reflecting overall live
quality (SF 36) or physical activity (Noyes) failed to
show this association. This might be explained by the
fact that these scores are influenced by much more
parameters than knee function. That the aspect knee
functionality plays an important role is shown by the
difference between the physical and the mental compo-
nent summary of the SF 36. Inclusion of more patients
could possibly lead to a statistical significance regarding
live quality or overall physical activity.
Although cartilage repair and inflammatory joint reac-
tions are usually associated with pain and loss of function
[41], this study could neither demonstrate regulatory
associations between both examined BMPs and the
inflammation-triggered IL-1b nor between BMPs and the
mediators of cartilage metabolism IGF-I and bFGF. This
m i g h tb ee x p l a i n e db yt h ef a c tt h a td i r e c tr e g u l a t i o n sin
vivo are rare; usually cytokines are controlled on different
regulatory levels making a distinguished mediator release
dependent on several affecting components possible.
The study does not allow drawing any conclusions
how BMP-2 is acting; we even may not determine what
part of the operation -arthrotomy or cartilage surgery
itself-induces the increase of BMP-2 levels. It also
remains unclear what molecular mechanisms are behind
the observed association. But the spectrum of BMP-2
effects concerning cartilage repair and differentiation is
rapidly growing [42,43]. We also may speculate that
BMP-2 plays a role in nervous tissue regeneration,
thereby influencing pain perception. A further interest-
ing aspect is the question, whether BMP-2 concentra-
tions are linked to differences in bone turnover induced
by damage of the subchondral bone layer during sur-
gery. This hypothesis would be supported by the better
correlations seen in patients undergoing microfracturing
compared to ACI patients. After all, the study does not
allow explaining the BMP-2 induced reactions. This lim-
itation is caused by the plain observational characteristic
of the study. We speculate that the cartilage in the near
surrounding of the defect and the synovia may play an
important role controlling BMP-2 release and that the
assembly of the different receptors influences
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was initiated in order to localize BMPs and their recep-
tors in the different regions of interest in the joint. This
will give the possibility to include other promising
representatives of the BMP-family with cartilage influen-
cing properties as BMP-4 [45].
Conclusions
Strong evidence has been collected so far that both
examined BMPs play a significant role in cartilage
repair. Our data could confirm intraarticular presence of
BMP-2 in patients with circumscribed cartilage lesions.
The concentrations were increased following cartilage
regenerating surgery and statistically significant corre-
lated with improvement of functional knee scores.
Therefore, BMP-2 seems to play a significant role in
cartilage maintenance and repair.
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